PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Ann Oncol
Prif Awduron: Marmorino, F., Cremolini, C., Loupakis, F., Antoniotti, C., Barbara, C., Dargenio, F., Miraglio, E., Masi, G., Salvatore, L., Schirripa, M., Borelli, B., Marcucci, L., Antonuzzo, L., Chiara, S., Banzi, C., Amoroso, D., Bonetti, A., Martignetti, A., Paris, M., Boni, L., Tomcikova, D., Falcone, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2016
Pynciau:
Abstracts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984152/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw200.04
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg